5 Results for "

BCR-ABL-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "BCR-ABL-IN-2" in MCE Product Catalog:

Cat. No.: HY-18819
CAS No.: 897369-18-5
Target:  

Bcr-Abl

Research Areas:  

Cancer

BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1 native and ABL1 T315I, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-11007
CAS No.: 778270-11-4
Purity:  99.82%
Research Areas:  

Cancer

GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC50 of 138 nM .
loading...
    loading...
Cat. No.: HY-150908
CAS No.: 1197958-90-9
Brigatinib A is an GID4 ligand. Brigatinib A can be used for synthesizing PROTAC BCR-ABL Degrader-2 (HY-174368) .
loading...
    loading...
Cat. No.: HY-11007R
CAS No.: 778270-11-4
Target:  

Bcr-Abl SARS-CoV

Research Areas:  

Cancer

GNF-2 (Standard) is the analytical standard of GNF-2. This product is intended for research and analytical applications. GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC50 of 138 nM .
loading...
    loading...
Cat. No.: HY-180967
CAS No.: 2703834-25-5
Target:  

Bcr-Abl PROTACs Apoptosis

Research Areas:  

Cancer

PROTAC BCR-ABL Degrader-2 is a selective Bcr-Abl T315 PROTAC degrader with a DC50 of 108.7 nM in Ba/F3 Bcr-Abl T315I cells. PROTAC BCR-ABL Degrader-2 exhibits the most potent degradation efficacy with DR of 69.89% and 94.23% at 100 and 300 nM, respectively. PROTAC BCR-ABL Degrader-2 demonstrates high plasma exposure, and induces significant tumor regression and induces tumor cell apoptosis with a good safety profile in vivo. PROTAC BCR-ABL Degrader-2 can be used for chronic myeloid leukemia (CML) research [2].
loading...
    loading...